CoChat

Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC).

Adams, Sylvia, Diamond, Jennifer Robinson, Hamilton, Erika Paige, Pohlmann, Paula Raffin, Tolaney, Sara M., Molinero, Luciana, He, Xian, Waterkamp, Daniel, Funke, Roel Peter, Powderly, John D. · 2016 · Journal of Clinical Oncology
Cited by 126

The DOI matches its Crossref record.

Abstract

1009 Background: Atezolizumab (atezo; MPDL3280A) is a humanized MAb that inhibits binding of PD-L1 to PD-1 and B7.1, thus restoring tumor-specific T-cell immunity. Atezo has single-agent activity in mTNBC. Combining atezo with chemotherapy is hypothesized to enhance tumor-specific T-cell immunity by exposing the immune system to high levels of tumor antigens and modulating T-cell and NK cell functions. This arm of a Phase Ib study evaluated atezo + nab-paclitaxel (pac) in patients (pts) with mTNBC treated with ≤ 3 prior lines of therapy. Methods: Primary endpoints were safety and tolerability; secondary endpoints included clinical activity. Pts received atezo 800 mg q2w (d1,15) and nab-pac 125 mg/m2 q1w (d1,8,15) q3 of 4 wks. After nab-pac discontinuation, maintenance atezo was allowed until loss of clinical benefit. ORR was assessed by RECIST v1.1. PD-L1 staining on tumor cells and tumor-infiltrating immune cells was scored using the SP142 IHC assay. Results: 32 pts were safety evaluable (median follow-up 5.21 mo [range 0.6-12.6]). All pts were female, with a median age of 56 y (range 32-84); 81% were ECOG PS 1, and 87% had prior taxanes. The most common treatment-related AE was decreased neutrophil count (53% all grade; 41% Gr 3-4). No DLTs or related deaths occurred. 24 pts (dosed by June 1, 2015) were efficacy evaluable (Table). 3 pts developed new lesions with PR in target lesions that were scored as RECIST PD, but remained on treatment with prolonged biologic response. Responses occurred in pts whose tumors expressed PD-L1 and in those with little to no PD-L1 expression. Nab-pac did not affect atezo-induced proliferation of circulating activated CD8+ T cells. Conclusions: These results are the first to demonstrate that atezo + nab-pac is tolerable with promising activity in mTNBC. Updated results and tissue correlates will be presented. An ongoing Phase III trial is evaluating this regimen in previously untreated mTNBC pts. Clinical trial information: NCT01633970.Best Response, % 1L n = 9 2L n = 8 3L+ n = 7 All pts N = 24 Confirmed ORR (95% CI) 67 (30, 93) 25 (3, 65) 29 (4, 71) 42 (22, 63) ORRa (95% CI) 89 (52, 100) 75 (35, 97) 43 (10, 82) 71 (49, 87) CR 11 0 0 4 PR 78 75 43 67 SD 11 25 29 21 a Including investigator-assessed unconfirmed responses.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2016.34.15_suppl.1009

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 126

Metadata

Authors
Adams, S., Diamond, J. R., Hamilton, E. P., Pohlmann, P. R., Tolaney, S. M., Molinero, L., He, X., Waterkamp, D., Funke, R. P., & Powderly, J. D.
Venue
Journal of Clinical Oncology
Published
2016-05-20
Volume
34
Issue
15_suppl
Pages
1009-1009
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2738968620
Cited by
126
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). https://app.cochat.ai/papers/10.1200/jco.2016.34.15_suppl.1009
The paper
Adams, S., Diamond, J. R., Hamilton, E. P., Pohlmann, P. R., Tolaney, S. M., Molinero, L., He, X., Waterkamp, D., Funke, R. P., & Powderly, J. D. (2016). Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). Journal of Clinical Oncology. https://doi.org/10.1200/jco.2016.34.15_suppl.1009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.